Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Outcomes of Pharmacy-Led Hepatitis C Direct-Acting Antiviral Utilization Management at a Veterans Affairs Medical Center. J Manag Care Spec Pharm 2017 Mar;23(3):364-369 PMID: 28230455

Abstract

BACKGROUND: The Veterans Affairs Health (VA) Administration has reported hepatitis C virus (HCV) infection rates among veterans to be twice that of the general U.S population. New HCV direct-acting antiviral (DAA) treatment options offer superior sustained virologic response (SVR) rates, improved side-effect profiles, and shortened treatment courses; yet, these new HCV DAAs are expensive, and utilization management strategies are needed to optimize use and improve clinical outcomes. A VA medical center uses pharmacist-led HCV DAA utilization management strategies that includes clinical guidance, optimizing operational flow, budget tracking and forecasting, and patient outcomes tracking.

OBJECTIVE: To assess the economic and clinical outcomes of pharmacy-led HCV DAA utilization management in a VA medical center.

METHODS: This was a single-center, retrospective cohort study. Patient electronic health records and the hepatitis C DAA outcomes tracking database were reviewed at a VA medical center. Patients with an HCV DAA prior authorization drug request and therapy initiated between October 1, 2014, and September 30, 2015, were included. The primary endpoint was the ratio of drug spend to cure rate calculated as the total dollars spent to the number of patients achieving SVR at least 12 weeks from end of treatment. Secondary endpoints included economic, clinical, and safety outcomes.

RESULTS: A total of 372 patients were included in the study. The overall cost ratio of total drug spend to cure rate was $40,135.22. The overall cure rate was 94.1%, with no discontinuations due to treatment failure. The ratio of drug spend to cure rate was $41,907.35 and $38,430.77 in cirrhotic and noncirrhotic patients, respectively, and $39,481.62 and $39,178.74 in treatment-experienced and naive patients, respectively. Ten patients discontinued therapy because of the adverse effects of anemia, nausea, vomiting, and anxiety. The medication possession ratio was 98.7% (± 0.13) for all patients included in the study.

CONCLUSIONS: This study suggests that pharmacist-led HCV DAA utilization management is an important factor in costs and cure rates. Utilization management strategies are valuable to help adequately manage patients with chronic hepatitis C (CHC) and may allow practitioners to maximize available funding for CHC, while maintaining high efficacy and safety.

DISCLOSURES: No outside funding supported this research. The authors have no conflicts of interest to report. Study concept and design were contributed primarily by Britt, along with Hashem, Brown, and Yang. Yang took the lead in data collection, along with Britt, and data interpretation was performed by all the authors. The manuscript was written and revised by Yang, Britt, Brown, and Hashem.

Author List

Yang S, Britt RB, Hashem MG, Brown JN

Author

Sendra Yang PharmD Clinical Assistant Professor in the School of Pharmacy department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Antiviral Agents
Female
Hepacivirus
Hepatitis C
Humans
Male
Middle Aged
Pharmaceutical Services
Pharmacy
Retrospective Studies
Treatment Failure
Treatment Outcome
Veterans



View this publication's entry at the Pubmed website PMID: 28230455
jenkins-FCD Prod-153 3ca6710ea990189ceb85f4312e7298b5922ce1a6